The global market of stem cell assay is anticipated to reach USD 1,367.3 Million by 2022 at a CAGR of 21.5% during 2016 to 2022. Due to Rising Investment in Research Related Activities, Funding for Stem Cell Research Technological Advancements. The global market of stem cell assay has been segmented on the basis of type of assay, detection, kit, instrument, end-user, application, and region. Major strategies adopted by key players are collaboration, product launch, partnership and acquisition and merger etc. The key players in the global market of stem cell assay are Promega Corporation (U.S.), GE Healthcare (U.K.), Thermo Fisher Scientific Inc. (U.S.), Cell Biolabs, Inc. (U.S.), Merck KGaA (Germany), Hemogenix Inc. (U.S.), Bio-Rad Laboratories, Inc (U.S.), STEMCELL Technologies Inc. (CA), Cellular Dynamics International, Inc. (U.S.) and Bio-Techne Corporation (U.S.).

Market growth can be recognized due to the increasing investment in research related activities, high prevalence of chronic diseases, and technological advancement. However, high cost of stem cell based therapies and stringent regulatory policies are key factors restraining the growth of this market.

The global market of stem cell assay has been segmented on the basis of type of, kit, detection, instrument assay, application, end-user, and region. On the basis of type of assay, the global market is segmented into viability/cytotoxicity, proliferation, differentiation, isolation & purification, cell identification, function and apoptosis. The viability/cytotoxicity segment is anticipated to be the major and fastest-growing segment of the global market in 2016; while, the isolation & purification segment is anticipated to grow at the highest CAGR during the coming period. The adult stem cell kits are again segmented into mesenchymal stem cell kits, hematopoietic stem cell kits, induced pluripotent stem cell kits (IPSCs), umbilical cord stem cell kits and neuronal stem cell kits. The adult stem cell kits segment is expected to witness the highest CAGR during 2016 to 2022. The huge growth in this segment can be chiefly attributed to the effectiveness of this type of kit in cell analysis.

Based on detection, the global market of stem cell assay has been segmented into detection and instruments kits. The instrument segment is estimated to witness the highest CAGR during 2016 to 2022. The huge growth in this segment is associated with the increasing demand for instrument from research and medical services.

On the basis of Geography, the stem cell assay market is segmented into Europe, North America, Asia pacific, and ROW. The market is dominated by North America, which is followed by Europe. Growth in the North American regions is chiefly driven by the increasing patient pool and rising incidence and prevalence of chronic diseases in North coming period. However, the RoW region is anticipated to witness the highest CAGR during the coming period. The huge growth in this segment is centered in the Middle East, Latin America, and Africa due to the rising adoption of stem cell based therapies in these region.

The key players in the global market of stem cell assay are Promega Corporation (U.S.), GE Healthcare (U.K.), Thermo Fisher Scientific Inc. (U.S.), Cell Biolabs, Inc. (U.S.), Merck KGaA (Germany), Hemogenix Inc. (U.S.), Bio-Rad Laboratories, Inc (U.S.), STEMCELL Technologies Inc. (CA), Cellular Dynamics International, Inc. (U.S.) and Bio-Techne Corporation (U.S.). Major strategies adopted by these key players are collaboration, product launch, partnership and acquisition and merger etc.